| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:1098.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
From the Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Correspondence to Dr Junichi Kiryu, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail kiryu{at}kuhp.kyoto-u.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: rats, inbred SHR ischemia leukocytes oxidative stress cell adhesion molecules
| Introduction |
|---|
|
|
|---|
It has been reported that transient ischemia in spontaneously hypertensive rats (SHR) leads to a greatly enhanced inflammatory reaction with organ injury in the heart,7 brain,8 and mesentery,9 as compared with age-matched Wistar-Kyoto rats (WKY). These reports then raise the question of whether hypertension may also be deleterious to ischemia/reperfusion injury in the retina via enhanced inflammatory reactions. The answer remains unclear.
Leukocytes play a central role in ischemia/reperfusion injury because they produce oxygen-derived free radicals that can cause tissue injury.10,11 Some studies showed that the antiradical effect of superoxide dismutase (SOD), which has been commonly used as free radical scavengers, on the production of oxygen free radicals in ischemia/reperfused rat retina.12 Leukocytes accumulate into tissues through the interactions with vascular endothelial cells and the interactions are mediated by intercellular adhesion molecule-1 (ICAM-1), which are expressed on vascular endothelium.13 We previously demonstrated in retina that the inhibition of ICAM-1 leads to decrease the leukocyteendothelial interactions and ischemia/reperfusion injury.14
The retinal microcirculation can be observed noninvasively, because the optic media, which consists of the cornea, lens, vitreous body, and retina, are transparent. In addition, every retina has an equal, limited, and relatively flat area. Therefore, the retinal microcirculation is suitable for quantitative analysis. In the present study, we evaluated the pathogenesis of hypertension and its effect on leukocyte dynamics, ICAM-1 expression, and retinal damage after transient retinal ischemia. In addition, we examined the effect of SOD on the retinal ischemia/reperfusion injury in SHR.
| Methods |
|---|
|
|
|---|
Because the pharmacological half-life (6 to 10 minutes) of SOD is relatively short, SOD conjugated to polyethylene glycol (PEG-SOD; Sigma, St Louis, Mo) was used in our experimental protocols, because it has a pharmacological half-life of 30 hours.17 The rats were treated with 15 000 U/kg of PEG-SOD intravenously 5 minutes before the induction of reperfusion. All experiments were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Evaluation of Blood Pressures, Major Retinal Vessel Diameters, and Leukocyte Count in Peripheral Blood
Each rat was anesthetized and the pupil of the right eye was dilated, as previously described.16 Systolic blood pressure was monitored at each time point in the tail of each rat by means of a sensing cuff attached to a blood pressure analyzer (IITC, Woodland Hills, Calif). To evaluate diameters of the major retinal vessels, the fundus was observed with a scanning laser ophthalmoscope (Rodenstock Instruments, Munich, Germany) as previously described.16 The peripheral blood sample was analyzed by a hematology analyzer (ERMA, Tokyo, Japan).
Flat-Mount Preparation for Evaluation of Leukocyte Accumulation
After the evaluation of major retinal vessel diameters and blood pressures, we evaluated leukocyte accumulation in the ischemia-reperfused retina. Acridine orange (Wako Pure Chemicals, Osaka, Japan) (0.1% solution in saline) was injected continuously through a catheter for 1 minute at a rate of 1 mL/min. Acridine orange emits green fluorescence when it interacts with DNA; nuclei of circulating leukocytes are thereby stained. Accordingly, a few minutes after acridine orange injection was stopped, the fluorescence of circulating leukocytes was faint because of the washout effect. In contrast, leukocytes that had accumulated in the retina remained fluorescent for 2 hours.16 At 30 minutes after injection of acridine orange, the retina was carefully removed and a flat-mount was prepared using a mounting medium for fluorescence (Vector Laboratories, Burlingame, Calif). The retina was then examined using a fluorescence microscope. For quantitative analysis, the number of accumulated leukocytes in high-power fields (x200) was counted and expressed as the average number per field (0.50 mm2) in 4 peripapillary areas examined.
Semiquantification of ICAM-1 Gene Expression by Reverse-Transcription Polymerase Chain Reaction Method
The eyes were enucleated at 24 hours after reperfusion. The retina was carefully isolated. Polymerase chain reaction was performed as previously described.18 The primers were AGCCTCAGGCCTAAGAGGAC (sense) and AGGGGTCCCAGAGAGGTCTA (antisense) for ICAM-1, and GGCATCCTGACCCTGAAGTA (sense) and GCCATCTCTTGCTCGAAGTC (antisense) for ß-actin, which was used as the internal standard.
Enzyme-Linked Immunosorbent Assay for ICAM-1
The eyes were enucleated at 48 hours after reperfusion and enzyme-linked immunosorbent assay was performed.19 The retina was carefully isolated, placed in 150 µL of lysis buffer (20% glycerol, 10 mmol/L KCl, 1 mmol/L MgCl2, 0.1% Triton, 300 mmol/L NaCl, 0.5 mmol/L DTT, 0.5 mmol/L PMSF, 20 mmol/L HEPES [pH 7.9]) and homogenized. The lysate was centrifuged at 14 000 rpm for 15 minutes at 4°C, and the ICAM-1 levels in the supernatant were determined with the ICAM-1 kit (Quantikine; R&D Systems, Minneapolis, Minn) according to the manufacturers protocol. Total protein was determined using the bicinchoninic acid (BCA) kit (Bio Rad, Hercules, Calif) and was used to normalize the ICAM-1 protein levels.
Histological Procedures
To investigate the effects of hypertension and the protective effect of SOD on retinal ischemia/reperfusion injury, we performed a quantitative histological analysis. After 14 days of reperfusion, the eyes were collected and stained with hematoxylin and eosin, and then the thickness of the overall retina was measured as previously described.13
Statistical Analysis
Data are reported as the mean±SEM. The data were analyzed by 1-way ANOVA, using a post hoc test with Fisher protected least-significance procedure. Unpaired t tests were used to compare results between groups at matched follow-up time points after reperfusion. Differences are considered to be statistically significant when the P values are <0.05.
| Results |
|---|
|
|
|---|
|
Major Retinal Vessel Diameters
Figure 1 indicates changes of major retinal vessel diameters in the rats at various time points after reperfusion. The diameters of major retinal arteries and veins of SHR were smaller at all time points compared with those of WKY. In arteries, slight vasoconstriction occurred gradually after reperfusion in both strains, reaching 0.85-fold (not significant) in WKY and 0.88-fold (not significant) in SHR at its minimum, compared with those of controls. In contrast, venous dilation was observed after reperfusion, reaching 1.4-fold in WKY (P=0.0008) and 1.5-fold in SHR (P=0.0007) at its maximum, compared with those of controls.
|
Leukocyte Accumulation
Figure 2 shows the leukocytes accumulated in the retina after transient ischemia. In control rats, only a few leukocytes were recognized in the retina, whereas accumulated leukocytes increased in the retina after transient ischemia. Figure 3 indicates changes in the number of leukocytes accumulated in the retina. The number of accumulated leukocytes peaked at 12 hours after reperfusion in WKY and at 48 hours after reperfusion in SHR. The number of accumulated leukocytes at 48 hours after reperfusion in SHR increased by 1.6-fold (P=0.033) compared with that in the WKY at 12 hours after reperfusion, and by 5.2-fold (P=0.0007) compared with that in the WKY at 48 hours after reperfusion.
|
|
The number of accumulated leukocytes in SOD-treated SHR and WKY at 48 hours after reperfusion was 45.5% (P=0.0071) and 94.7% (not significant), respectively, of that in the vehicle-treated rats of each strain at 48 hours after reperfusion. The data demonstrated significant protection effect of SOD on the leukocyte accumulation after transient ischemia in SHR.
Gene Expression and Protein Levels of ICAM-1 in the Retina
The levels of ICAM-1 mRNA expression in retinal ischemia/reperfusion-induced rats of both strains and in sham-operated SHR were evaluated as a ratio of the average values of sham-operated WKY. There were no significant differences in ICAM-1 mRNA expression between sham-operated WKY and SHR. In contrast, ICAM-1 mRNA expression in the retinas of the SHR at 24 hours after reperfusion was increased by 2.1-fold (P=0.0136) compared with those of the sham-operated SHR, and it was increased by 2.9-fold (P=0.0008) compared with those of WKY at 24 hours after reperfusion. This finding was substantiated by enzyme-linked immunosorbent assay. The ICAM-1 protein level in the vehicle-treated SHR at 48 hours after reperfusion was upregulated to 2.39-fold (P<0.0001) of the sham-operated SHR and upregulated to 1.15-fold (P=0.0157) of the WKY at 48 hours after reperfusion.
Histological Study
Histological examination showed differences of the thickness of the retinas among the 3 groups (sham-operated, vehicle-treated, and SOD-treated rats) in both strains (Figure 4). There were no significant differences in thickness of sham-operated retinas between each strain. The thickness of the retinas in the vehicle-treated SHR was significantly reduced to 72.0% (P=0.0012) of that in the sham-operated SHR and 84.3% (P=0.0084) of that in the vehicle-treated WKY. The data demonstrated significant greater ischemia-reperfused retinal damage in the vehicle-treated SHR. With treatment by SOD, however, structure of the postischemic retinas was preserved in SHR. The thickness of the retinas in SOD-treated SHR was 85.1%(not significant) of that in the sham-operated SHR and 118.2% (P=0.018) of that in the vehicle-treated SHR. There were no significant differences in thickness of SOD-treated retinas between each strain. The data demonstrated significant protection effect of SOD on retinal damage after transient ischemia in SHR.
|
| Discussion |
|---|
|
|
|---|
Previous studies have shown that the level of ICAM-1 expression is significantly higher in the microvasculature of SHR than in that of WKY.20 Our findings also showed that ICAM-1 mRNA expression and ICAM-1 protein level in the retinas after transient ischemia of SHR was increased compared with those of WKY. In addition, ICAM-1 has been reported to play an important role in leukocyteendothelial cell interactions during ischemia/reperfusion, and that inhibition of the adhesion molecule markedly decreases leukocyte accumulation and retinal damage subsequent to transient ischemia.14 Therefore, increased ICAM-1 mRNA expression and ICAM-1 protein level in the retinas of SHR might lead to increased leukocyte accumulation in the retinas of SHR compared with the one seen in WKY.
A significant amount of NO produced by SHR may be consumed by enhanced superoxide anion.21 Both leukocyte accumulation and the production of oxygen-free radicals may contribute to tissue injury after transient ischemia.22,23 Schmid-Schonbein et al24 have shown that organ injury in SHR might be related to a greater proportion of spontaneously activated granulocytes and an increased spontaneous production of xanthine oxidase-derived oxidants in the microvasculature. Endogenous scavenging mechanisms may thus be overwhelmed by a burst of radical production during reperfusion or reoxygenation.
In this study, with treatment by SOD, retinal damage during ischemia/reperfusion injury was reduced in SHR. SOD is known to play an important role as a free-radical scavenger and can lead to a reduction of leukocyte migration after transient ischemia,25 and thereby can prevent the production of oxygen free radicals by leukocytes, especially in SHR. Szabo et al26 showed the effects of SOD on ion shifts after retinal transient ischemia in SHR. They reported that oxidative stress is one possible factor involved in the pathogenesis of retinal ischemia/reperfusion damage in SHR, and SOD reduced the retinal reperfusion-induced ionic imbalance. From these results and our results, it is clear that retinal injury after transient ischemia in SHR is closely related to oxidative stress and can be reduced by treatment with SOD.
In addition, nitric oxide has been reported to play an important role in vasodilation.27 Our current data show that the diameters of major retinal arteries and veins of SHR are smaller than those of WKY after transient ischemia. These findings might be explained by reduced bioavailability of nitric oxide-derived from the endothelial cells in SHR.
Perspectives
We demonstrated that SHR show increased leukocyte accumulation in the retinas and greater retinal damage after transient ischemia compared with WKY. These findings may be based partially on oxidative stress produced by leukocytes accumulated in the postischemic retina. These considerations warrant further investigation to develop a novel therapy for the many ocular ischemic diseases associated with hypertension by focusing not only on blood pressure control but also on oxidative stress. In addition, because the retina is part of the central nervous system, we may be able to extrapolate the results of the present study for the benefit of future studies of postischemic brain injury.
| Acknowledgments |
|---|
Received October 22, 2003; first decision November 3, 2003; accepted February 10, 2004.
| References |
|---|
|
|
|---|
2. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997; 115: 741747.
3. Klein R, Klein BE, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1997; 95: 329350.[Medline] [Order article via Infotrieve]
4. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996; 114: 545554.
5. Hirvela H, Laatikainen L. Visual acuity in a population aged 70 years or older; prevalence and causes of visual impairment. Acta Ophthalmol Scand. 1995; 73: 99104.[Medline] [Order article via Infotrieve]
6. Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology. 1982; 89: 11321145.[Medline] [Order article via Infotrieve]
7. Batist G, Mersereau W, Malashenko BA, Chiu RC. Response to ischemia-reperfusion injury in hypertrophic heart. Role of free-radical metabolic pathways. Circulation. 1989; 80: III1013.[Medline] [Order article via Infotrieve]
8. Tagami M, Yamagata K, Ikeda K, Fujino H, Nara Y, Nakagawa K, Kubota A, Numano F, Yamori Y. Genetic vulnerability of cortical neurons isolated from stroke-prone spontaneously hypertensive rats in hypoxia and oxygen reperfusion. Hypertens Res. 1999; 22: 2329.[Medline] [Order article via Infotrieve]
9. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, Schmid-Schonbein GW. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A. 1998; 95: 47544759.
10. Ferrari R, Ceconi C, Curello S, Cargnoni A, Alfieri O, Pardini A, Marzollo P, Visioli O. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med. 1991; 91: 95S105S.[Medline] [Order article via Infotrieve]
11. Curello S, Ceconi C, de Giuli F, Panzali AF, Milanesi B, Calarco M, Pardini A, Marzollo P, Alfieri O, Messineo F, Ferrari R. Oxidative stress during reperfusion of human hearts: potential sources of oxygen free radicals. Cardiovasc Res. 1995; 29: 118125.[CrossRef][Medline] [Order article via Infotrieve]
12. Szabo ME, Droy-Lefaix MT, Doly M. Direct measurement of free radicals in ischemic/reperfused diabetic rat retina. Clin Neurosci. 1997; 4: 240245.[Medline] [Order article via Infotrieve]
13. Nishijima K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Yamashiro K, Kamizuru H, Ieki Y, Tanihara H, Honda Y, Ogura Y. Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003; 44: 332341.
14. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Tojo SJ, Miyasaka M, Honda Y. Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. Invest Ophthalmol Vis Sci. 1999; 40: 11831190.
15. Tsujikawa A, Kiryu J, Yamashiro K, Nonaka A, Nishijima K, Honda Y, Ogura Y. Interactions between blood cells and retinal endothelium in endotoxic sepsis. Hypertension. 2000; 36: 250258.
16. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda Y. In vivo evaluation of leukocyte dynamics in retinal ischemia/reperfusion injury. Invest Ophthalmol Vis Sci. 1998; 39: 793800.
17. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol. 1989; 21: 12411251.[CrossRef][Medline] [Order article via Infotrieve]
18. Miyahara S, Kiryu J, Tsujikawa A, Katsuta H, Nishijima K, Miyamoto K, Yamashiro K, Nonaka A, Honda Y. Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. Stroke. 2003; 34: 20432049.
19. Miyahara S, Kiryu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, Katsuta H, Nishijima K, Tsujikawa A, Honda Y. Simvastatin Inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-Induced diabetes. Am J Pathol. In Press.
20. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM, Siren AL. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol. 1996; 270: H21252131.[Medline] [Order article via Infotrieve]
21. Wiemer G, Itter G, Malinski T, Linz W. Decreased nitric oxide availability in normotensive and hypertensive rats with failing hearts after myocardial infarction. Hypertension. 2001; 38: 13671371.
22. Werns SW, Shea MJ, Lucchesi BR. Free radicals in ischemic myocardial injury. J Free Radic Biol Med. 1985; 1: 103110.[CrossRef][Medline] [Order article via Infotrieve]
23. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol. 1986; 251: G567G574.[Medline] [Order article via Infotrieve]
24. Schmid-Schonbein GW, Seiffge D, DeLano FA, Shen K, Zweifach BW. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension. 1991; 17: 323330.
25. Suzuki M, Inauen W, Kvietys PR, Grisham MB, Meininger C, Schelling ME, Granger HJ, Granger DN. Superoxide mediates reperfusion-induced leukocyte-endothelial cell interactions. Am J Physiol. 1989; 257: H1740H1745.[Medline] [Order article via Infotrieve]
26. Szabo ME, Droy-Lefaix MT, Doly M. Modification of reperfusion-induced ionic imbalance by free radical scavengers in spontaneously hypertensive rat retina. Free Radic Biol Med. 1992; 13: 609620.[CrossRef][Medline] [Order article via Infotrieve]
27. Nilsson SF. Nitric oxide as a mediator of parasympathetic vasodilation in ocular and extraocular tissues in the rabbit. Invest Ophthalmol Vis Sci. 1996; 37: 21102119.
This article has been cited by other articles:
![]() |
G. Tezel, X. Yang, and J. Cai Proteomic Identification of Oxidatively Modified Retinal Proteins in a Chronic Pressure-Induced Rat Model of Glaucoma Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3177 - 3187. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tamura, K. Miyamoto, J. Kiryu, S. Miyahara, H. Katsuta, F. Hirose, K. Musashi, and N. Yoshimura Intravitreal Injection of Corticosteroid Attenuates Leukostasis and Vascular Leakage in Experimental Diabetic Retina Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1440 - 1444. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |